$VMD earnings report

Viemed Healthcare Announces Third Quarter 2026 Financial Results. AlphAI read Viemed Healthcare's Third quarter 2026 filing as solid. 2 quarters are on record below.

Third quarter 2026

AlphAI · Earnings readVMD · Third quarter 2026 · ended September 30, 2026

Viemed Healthcare Announces Third Quarter 2026 Financial Results

✓Solid quarter

Record quarterly revenue of $80.7 million grew 12.2% year over year and 3.3% sequentially, while attributable net income and Adjusted EBITDA increased sequentially. The company raised the low end of revenue guidance, narrowed Adjusted EBITDA guidance, and lowered its net capital expenditure outlook.

Revenue
$80.7M
12.2% y/y · 3.3% q/q
Ventilator rental revenue
$37.5M
7.4% y/y
EPS · GAAP
$ 0.11
Full year ending December 31, 2026 outlook
$316 million to $320 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenue, three months ended September 30, 2026GAAP$80.67M3.3%12.2%
Revenue, nine months ended September 30, 2026GAAP$234.2M––
Cost of revenue, three months ended September 30, 2026GAAP$34.48M––
Cost of revenue, nine months ended September 30, 2026GAAP$100.1M––
Gross profit, three months ended September 30, 2026GAAP$46.19M––
Gross profit, nine months ended September 30, 2026GAAP$134.1M––
Selling, general and administrative expense, three months ended September 30, 2026GAAP$35.51M––
Selling, general and administrative expense, nine months ended September 30, 2026GAAP$107.4M––
Research and development expense, three months ended September 30, 2026GAAP$501K––
Research and development expense, nine months ended September 30, 2026GAAP$1.58M––
Stock-based compensation, three months ended September 30, 2026GAAP$2.48M––
Stock-based compensation, nine months ended September 30, 2026GAAP$6.96M––
Income from operations, three months ended September 30, 2026GAAP$6.96M––
Income from operations, nine months ended September 30, 2026GAAP$15.72M––
Net income, three months ended September 30, 2026GAAP$4.74M––
Net income, nine months ended September 30, 2026GAAP$10.35M––
Net income attributable to Viemed Healthcare, Inc., three months ended September 30, 2026GAAP$4.64M67.8%32.0%
Net income attributable to Viemed Healthcare, Inc., nine months ended September 30, 2026GAAP$9.98M––
Diluted net income per share, three months ended September 30, 2026GAAP$ 0.11––
Diluted net income per share, nine months ended September 30, 2026GAAP$ 0.24––
Adjusted EBITDA, quarter ended September 30, 2026non-GAAP$17.06M24.4%5.8%
Adjusted EBITDA as a percentage of net revenue, quarter ended September 30, 2026non-GAAP21.1%approximately 350 basis points–
Net cash provided by operating activities, nine months ended September 30, 2026GAAP$35.46M––
Net cash provided by operating activities, quarter ended September 30, 2026GAAP$11.49M––
Net cash provided by operating activities, trailing twelve months ended September 30, 2026GAAP$53.90M––
Free cash flow, quarter ended September 30, 2026non-GAAP$4.03M––
Free cash flow, trailing twelve months ended September 30, 2026non-GAAP$26.06M––

Segments

SegmentRevenueq/qy/y
Ventilator rental revenueSupported by higher average patient volumes.$37.5M–7.4%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Full year ending December 31, 2026 outlook

  • Revenue$316 million to $320 million
  • NoteAdjusted EBITDA is expected to range from $64 million to $66 million.
  • NoteNet capital expenditures are now expected to range from 8.0% to 9.0% of net revenue.
  • NoteThis outlook excludes the impact of potential future acquisitions or other strategic transactions.

Capital returns

  • During the quarter, the Company repaid $2.1 million of term debt.
  • During the quarter, the Company repurchased 115,000 common shares for approximately $1.0 million (excluding taxes).
  • Payments for share repurchase programs were $ 7,738 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026.
  • Shares redeemed to pay income tax were $ 2,082 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026.

What drove it

  • Ventilator rental revenue was supported by higher average patient volumes.
  • PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861 during the third quarter.
  • Sleep resupply patients increased 22.1% year over year and 10.5% sequentially to 40,918.
  • The company cited continued growth across its respiratory, sleep, and women's health businesses.
  • The updated outlook reflects reduced capital intensity as less capital-intensive product and service offerings contribute a greater share of revenue.

Concerns

  • Adjusted EBITDA increased 5.8% year over year, below the 12.2% year-over-year increase in quarterly net revenue.
  • Net cash provided by operating activities was $ 35,460 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026, while accounts receivable, net changed by $ (9,301) (Expressed in thousands of U.S. Dollars).
  • The company narrowed its Adjusted EBITDA guidance range to $64 million to $66 million from the previous range of $64 million to $68 million.
  • Cash and cash equivalents declined to $ 9,676 (Expressed in thousands of U.S. Dollars) at September 30, 2026 from $ 13,501 (Expressed in thousands of U.S. Dollars) at December 31, 2025.

What to watch

  • Whether the anticipated sequential improvement in revenue and Adjusted EBITDA in the fourth quarter is delivered.
  • Ventilator patient volumes, which totaled 12,552 as of September 30, 2026.
  • Growth in PAP therapy and sleep resupply patient counts.
  • Execution of the 8.0% to 9.0% of net revenue net capital expenditure outlook.
  • Progress in operating efficiency initiatives and the contribution of less capital-intensive offerings.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 9,676 (Expressed in thousands of U.S. Dollars) at September 30, 2026, compared with $ 13,501 (Expressed in thousands of U.S. Dollars) at December 31, 2025.
  • Working capital was $12.0 million at September 30, 2026.
  • Approximately $46 million was available under existing credit facilities at September 30, 2026.
  • Current portion of long-term debt was $ 511 (Expressed in thousands of U.S. Dollars) and long-term debt was $ 4,510 (Expressed in thousands of U.S. Dollars) at September 30, 2026.
  • Purchase of property and equipment was $ 23,788 (Expressed in thousands of U.S. Dollars) for the nine months ended September 30, 2026, compared with $ 31,248 (Expressed in thousands of U.S. Dollars) in the prior-year period.
  • Net CAPEX was $ 7,462 (Expressed in thousands of U.S. Dollars) for the quarter ended September 30, 2026 and $ 27,845 (Expressed in thousands of U.S. Dollars) for the trailing twelve months ended September 30, 2026.

Analysis

Viemed reported record third-quarter net revenue of $80.7 million, up 12.2% from the prior-year quarter and 3.3% sequentially. The company attributed performance to continued growth across respiratory, sleep, and women's health businesses. Ventilator rental revenue rose 7.4% year over year to $37.5 million, supported by higher average patient volumes, while the period-end ventilator patient count was 12,552.

Patient growth was strongest in the newer sleep-related metrics disclosed. PAP therapy patients increased 37.5% year over year and 16.0% sequentially to 43,861, and sleep resupply patients increased 22.1% year over year and 10.5% sequentially to 40,918. These metrics accompany management's description of a diversified platform and its statement that less capital-intensive offerings are contributing a greater share of revenue.

Profitability improved sequentially. Net income attributable to Viemed was $ 4,638 (Expressed in thousands of U.S. Dollars), compared with $ 2,764 (Expressed in thousands of U.S. Dollars) in the preceding quarter, and Adjusted EBITDA was $ 17,057 (Expressed in thousands of U.S. Dollars), compared with $ 13,715 (Expressed in thousands of U.S. Dollars). Adjusted EBITDA as a percentage of net revenue rose to 21.1% from 17.6%. Year over year, however, Adjusted EBITDA increased 5.8%, while quarterly net revenue increased 12.2%.

Cash generation included $ 11,487 (Expressed in thousands of U.S. Dollars) of quarterly operating cash flow and $ 4,025 (Expressed in thousands of U.S. Dollars) of quarterly free cash flow. The company ended the quarter with $ 9,676 (Expressed in thousands of U.S. Dollars) of cash and cash equivalents, repaid $2.1 million of term debt during the quarter, and repurchased 115,000 common shares for approximately $1.0 million excluding taxes.

The company raised the low end of its full-year net revenue range to $316 million to $320 million from $314 million to $320 million. It narrowed Adjusted EBITDA guidance to $64 million to $66 million from $64 million to $68 million and reduced its net capital expenditure outlook to 8.0% to 9.0% of net revenue from 8.5% to 10.0%. Management expects sequential improvement in both revenue and Adjusted EBITDA in the fourth quarter.

Management, verbatim

Viemed delivered another record quarter, with revenue reaching $80.7 million and continued growth across our respiratory, sleep, and women's health businesses. This marks our first full year-over-year quarterly comparison following the Lehan acquisition, and achieving double-digit revenue growth underscores the strength of our increasingly diversified platform and the opportunities ahead of us.

Casey Hoyt, CEO

We are particularly pleased with the improvement in profitability this quarter. Our attributable net income increased 68% sequentially, while Adjusted EBITDA grew 24%, significantly outpacing revenue growth and demonstrating improved operating leverage. These results reflect the progress we anticipated following our investments earlier this year, and we see additional opportunities to improve efficiency as those initiatives mature. We remain focused on expanding our reach, delivering high-quality patient care, and building on this momentum as we finish the year.

Casey Hoyt, CEO

Not in the filing

stated, not guessed
  • GAAP gross margin was not reported.
  • Quarterly GAAP operating cash flow for the prior-year quarter was not reported.
  • Quarterly free cash flow for the prior-year quarter was not reported.
  • GAAP EPS sequential comparison was not reported.
  • Segment revenue beyond ventilator rental revenue was not reported.
  • Dividend information was not reported.
  • A GAAP reconciliation for full-year Adjusted EBITDA guidance was not available without unreasonable effort, as stated by the company.
  • The previous outlook covered the full year 2026 only, and this quarterly release cannot be compared with full-year guidance.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readVMD · second quarter 2026 · ended June 30, 2026

Viemed reported record quarterly net revenues of $78.1 million, up 23.9%, while updating full-year 2026 revenue, Adjusted EBITDA and net capital expenditure guidance.

✓Solid quarter

Record revenue, accelerating PAP therapy and sleep resupply patient growth, positive operating and free cash flow, debt repayment and share repurchases support a solid result. Adjusted EBITDA decreased 4.0% year over year and the Adjusted EBITDA guidance range moved lower.

Revenue
$78.1M
increase of $15.0 million, or 23.9% y/y · increase of approximately 3.6% sequentially q/q
EPS · GAAP
$0.07
full year ending December 31, 2026 outlook
$314 million to $320 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net revenuesGAAP$78.1Mincrease of approximately 3.6% sequentiallyincrease of $15.0 million, or 23.9%
Net income attributable to ViemedGAAP$2.8M––
Diluted earnings per shareGAAP$0.07 per diluted share––
Adjusted EBITDAnon-GAAP$13.7M–4.0% decrease
Net cash provided by operating activitiesGAAP$15.9M––
Net cash provided by operating activities, trailing twelve months ended June 30, 2026GAAP$60.8M––
Free cash flownon-GAAP$8.6M––
Free cash flow, trailing twelve months ended June 30, 2026non-GAAP$34.4M––
Ventilator patientsother12,6354.5% sequential increase from March 31, 2026increase of 4.0% over June 30, 2025
PAP therapy patient countother37,8255.3% sequential increase from March 31, 2026increase of 44.0% over June 30, 2025
Sleep resupply patient countother37,03510.0% sequentiallyup 46.7% year over year
Cash balanceGAAP$10.7M––
Overall working capital balanceGAAP$6.1M––
Long-term debtGAAP$6.4M––
Available under existing credit facilitiesother$46M––

full year ending December 31, 2026 outlook

  • Revenue$314 million to $320 million
  • NoteAdjusted EBITDA is now expected to range from $64 million to $68 million.
  • NoteNet capital expenditures are now expected to range from 8.5% to 10.0% of net revenue.

Capital returns

  • Repurchased and cancelled 530,802 common shares under its share repurchase program at a cost of $5.1 million (excluding taxes).
  • Average buyback price of $9.65 per share.

What drove it

  • Net revenues set a Company record.
  • Strong ventilator setup activity and improving patient compliance.
  • Record PAP volume.
  • Continued expansion in resupply and maternal health.
  • The revised guidance reflects the growing contribution from less capital-intensive product and service revenue.

Concerns

  • Adjusted EBITDA decreased 4.0% compared with the quarter ended June 30, 2025.
  • The prior-year period included a $1.0 million non-recurring gain on disposal of property and equipment related to the ventilator return program, which benefited net income and concluded during 2025.
  • Adjusted EBITDA guidance was revised to $64 million to $68 million from $65 million to $69 million.
  • The updated full-year net revenue guidance retained the prior high end of $320 million.

What to watch

  • Ventilator patient growth following the record census of 12,635 patients as of June 30, 2026.
  • PAP therapy and sleep resupply patient-count growth.
  • Delivery against full-year net revenue guidance of $314 million to $320 million.
  • Delivery against full-year Adjusted EBITDA guidance of $64 million to $68 million.
  • Net capital expenditures relative to the updated 8.5% to 10.0% of net revenue outlook.
  • Further use of cash generation for term-loan repayment, platform investments and share repurchases.

Balance sheet and cash flow

  • Net cash provided by operating activities totaled $15.9 million for the quarter.
  • Net cash provided by operating activities totaled $60.8 million for the trailing twelve months ended June 30, 2026.
  • Free cash flow totaled $8.6 million for the quarter.
  • Free cash flow totaled $34.4 million for the trailing twelve months ended June 30, 2026.
  • Cash balance was $10.7 million as of June 30, 2026.
  • Overall working capital balance was $6.1 million as of June 30, 2026.
  • Repaid $2.2 million of its term loan during the quarter ended June 30, 2026.
  • Long-term debt totaled $6.4 million.
  • The Company has $46 million available under existing credit facilities.

Analysis

Viemed delivered record quarterly net revenues of $78.1 million, with reported growth of $15.0 million, or 23.9%, versus the prior-year quarter and approximately 3.6% sequentially. The operational indicators were also positive. Ventilator patients reached a record 12,635, while PAP therapy patients and sleep resupply patients reached 37,825 and 37,035, respectively. The latter two patient populations posted substantially faster reported year-over-year growth than the ventilator census.

Profitability and cash generation were positive, though the release identifies an important year-over-year divergence. Net income attributable to Viemed was $2.8 million, or $0.07 per diluted share, and Adjusted EBITDA was $13.7 million. Adjusted EBITDA was down 4.0% from the quarter ended June 30, 2025. Management noted that the prior-year period included a $1.0 million non-recurring gain on disposal of property and equipment related to the ventilator return program, which concluded during 2025.

Cash flow supported capital allocation and balance-sheet actions. The company generated $15.9 million of net cash provided by operating activities and $8.6 million of free cash flow in the quarter. It repurchased and cancelled 530,802 common shares for $5.1 million, excluding taxes, and repaid $2.2 million of its term loan. At quarter-end, Viemed reported $10.7 million of cash, $6.1 million of overall working capital, $6.4 million of long-term debt and $46 million available under existing credit facilities.

The full-year outlook update is mixed across metrics. Viemed raised the low end of net revenue guidance and narrowed the range to $314 million to $320 million from $312 million to $320 million. Conversely, it revised Adjusted EBITDA guidance to $64 million to $68 million from $65 million to $69 million. The company also lowered its net capital expenditure outlook to 8.5% to 10.0% of net revenue from 9.0% to 10.5%, citing the growing contribution from less capital-intensive product and service revenue.

The central items for the second half are whether record ventilation activity, patient compliance, PAP volume, resupply and maternal health expansion convert into delivery at the revised revenue range, and whether that growth supports the updated Adjusted EBITDA range. Capital intensity, as measured against the revised net capital expenditure outlook, and continued cash deployment among debt reduction, platform investment and repurchases remain important reported execution points.

Management, verbatim

Viemed delivered another record quarter, with revenue reaching $78.1 million and our ventilator patient census rising to the highest level in company history. Strong ventilator setup activity, improving patient compliance, record PAP volume, and continued expansion in resupply and maternal health demonstrate the momentum building across our entire platform.

Casey Hoyt, CEO

The strength of these results reflects the durable and increasingly diversified company we have built. Viemed has multiple growth engines, strong cash generation, a solid balance sheet, and the financial flexibility to continue investing in our people, technology, and patient care capabilities. We are making those investments deliberately to support the patient growth already entering the platform, and we enter the second half of 2026 confident in Viemed's ability to deliver consistent and increasingly predictable growth.

Casey Hoyt, CEO

Not in the filing

stated, not guessed
  • The filing text supplied is truncated before the accompanying financial-statement tables and non-GAAP reconciliations.
  • Prior-year and prior-quarter net revenue amounts were not printed on the net revenues line.
  • Prior-year and prior-quarter net income attributable to Viemed were not provided.
  • Prior-year and prior-quarter diluted earnings per share were not provided.
  • Prior-year Adjusted EBITDA amount was not provided.
  • Prior-year and prior-quarter operating cash flow amounts were not provided.
  • Prior-year and prior-quarter free cash flow amounts were not provided.
  • Gross profit and gross margin were not provided.
  • Operating income, operating expenses and operating margin were not provided.
  • GAAP and non-GAAP tax-rate figures were not provided.
  • GAAP and non-GAAP reconciliation details were not provided.
  • Segment revenue disclosures were not provided.
  • Six-month financial results were not provided in the supplied text.
  • Dividend information was not provided.
  • Prior-release outlook was not provided; therefore, no actual-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about VMD earnings dates

When is Viemed Healthcare's next earnings date?
AlphAI has no date for VMD yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.